Figure 4.
Effects of selumetinib on human CRC and NSCLC xenografts. Mice bearing (A) HCT116, (B) Calu3, (C) HCT15, and (D) H460 cancer cells were treated with vehicle or selumetinib (25 or 50 mg kg−1, oral, BID) for 21 days (n=10 mice per group). Treatments started when tumour reached volumes of 100–150 mm3. Animals were killed when tumour reached 2000, mm3 in size. ** P<0.005; ***P<0.0005.